Fulltext

Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study

Onal, C. ; Li, Y. X. ; Miller, R. C. ; Poortmans, P. ; Constantinou, N. ; Weber, D. C. ; Atasoy, B. M. ; Igdem, S. ; Ozsahin, M. ; Ozyar, E.

In: Annals of Oncology, 2011, vol. 22, no. 1, p. 156-164

Ajouter à la liste personnelle
    Titre
    • Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
    Auteur
    • Onal, C.. Department of Radiation Oncology, Baskent University Medical Faculty, Adana, Turkey
    • Li, Y. X.. Cancer Hospital/Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China
    • Miller, R. C.. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA
    • Poortmans, P.. Department of Radiation Oncology, Institute Verbeeten, Tilburg, The Netherlands
    • Constantinou, N.. The Hematology Clinic, Theagenion Cancer Hospital, Thessaloniki, Greece
    • Weber, D. C.. Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • Atasoy, B. M.. Department of Radiation Oncology, Marmara University School of Medicine, Istanbul
    • Igdem, S.. Department of Radiation Oncology, Metropolitan Hospital, Istanbul, Turkey
    • Ozsahin, M.. Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    • Ozyar, E.. Department of Radiation Oncology, Acibadem University, Istanbul, Turkey
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2011, vol. 22, no. 1, p. 156-164. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:291848
    Summary
    Background: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74% and 71%, respectively, and the disease-free survival (DFS) rates were 68% and 64%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma